Biotech Values

[DewDiligence]

ICPT –16% on Ocaliva safety warning:

https://t.co/fFsTjIEa2w

Liver injury, liver decompensation, liver failure, and death have been reported in patients with moderate to severe hepatic impairment when OCALIVA was dosed more frequently than recommended in labeling for such patients. In addition, serious liver adverse events have been reported in patients initiating therapy without cirrhosis or with mild liver impairment. Liver- related adverse events have occurred both early in treatment and after months of treatment.

It shouldn't be a surprise that Ocaliva has bad side effects—no optimization was ever performed on this purportedly "natural" compound.